MedTrace Logo

Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months

NCT04260152 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-08-10

No results posted yet for this study

Summary

This double blind, randomized, split mouth study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for the treatment of Miller Class I or II recession defects at 6 months post treatment.

Conditions

  • Gingival Recession

Interventions

DEVICE

Geistlich Fibro-Gide

Surgical recession root coverage with coronally advanced flap in combination with Geistlich Fibro-Gide

PROCEDURE

Connective Tissue Graft (CTG

Surgical recession root coverage with coronally advanced flap in combination with CTG

Sponsors & Collaborators

  • Medelis Inc.

    collaborator INDUSTRY

  • Geistlich Pharma AG

    lead INDUSTRY

Principal Investigators

  • Michael K McGuire, DDS MSD · PerioHealth Professionals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2020-01-04
Completion
2020-07-22
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04260152 on ClinicalTrials.gov